Vertex Pharmaceuticals (VRTX -2.3%) and partner Alios BioPharma say they've decided to discontinue development of their hepatitis C virus drug candidate ALS-2158 due to disappointing results, but plan to begin Phase II testing of ALS-2200, an orally administered HCV drug regimen, by the end of the year. The companies hope to run one Phase II test of the drug in combination with Ribvarin, and a second testing with VRTX's recently approved HCV therapy Incivek.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs